Drupal.behaviors.print = function(context) {window.print();window.close();}>

Cancer Genetics Again Lowers Expected Proceeds from IPO to $23.5M

February 14, 2013

Cancer Genetics Again Lowers Expected Proceeds from IPO to $23.5M

By a GenomeWeb staff reporter

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories

Underwriters Exercise Over-allotment Option on Cancer Genetics IPO

April 8, 2013 / GenomeWeb Daily News
Cancer Genetics Prices IPO; Expects $6M in Proceeds

April 5, 2013 / GenomeWeb Daily News
Cancer Genetics Partners with Gilead on CLL Clinical Trials; Revises Expected Proceeds from IPO

March 12, 2013 / GenomeWeb Daily News
Cancer Genetics Lowers Expected Proceeds from IPO, Increases 2012 Revenues

March 4, 2013 / GenomeWeb Daily News
Cancer Genetics Revises IPO Filing, Targets $29.3M in Proceeds

February 13, 2013 / GenomeWeb Daily News